BC Week In Review | Aug 8, 2011
Clinical News

ALX-0081: Interim Phase II data

Interim data from 5 patients in the ongoing, single-blind, international Phase II TITAN trial showed that ALX-0081 followed by ALX-0681 inhibited vWF-mediated clotting as measured by a reduction in ristocetin cofactor compared to placebo. The...
BC Week In Review | Jan 4, 2010
Clinical News

Anti-vWF Nanobody: Extension study data

Data from 22 patients with stable angina undergoing percutaneous coronary intervention (PCI) in the open-label extension of a Phase Ib trial showed that IV ALX-0081 significantly inhibited vWF-mediated clotting as measured by complete inhibition of...
BC Week In Review | Aug 24, 2009
Clinical News

ALX-0681: Phase I data

Data from 36 healthy volunteers in a double-blind, placebo-controlled, single and multiple dose Phase I trial showed that daily injections of 10 mg ALX-0681 achieved complete inhibition of ristocetin cofactor for >14 days. There were...
Items per page:
1 - 3 of 3